Metagenomic Sequencing Market

Illumina (US) and Thermo Fisher Scientific (US) are the Leading Player in the Metagenomic Sequencing Market

The metagenomic sequencing market is expected to reach USD 4.3 billion by 2027 from USD 1.9 billion in 2022, at a CAGR of 18.4% during the forecast period. Growth in the metagenomic sequencing market is mainly driven by continuous technological innovations in NGS platforms, increasing initiatives and funding from government & private bodies for large-scale sequencing projects, declining costs of genome sequencing, and the significant applications of metagenomics in various fields.

Illumina, Inc. (US), Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), and Oxford Nanopore Technologies Plc. (UK) are the prominent players operating in the metagenomic sequencing market.

To know about the assumptions considered for the study download the pdf brochure

Illumina (US) is the leading player in the metagenomic sequencing market, accounting for the largest share of the market in 2020. This is attributed to its robust product offerings and NGS services. The company’s product segment includes a wide range of sequencing, genotyping, gene expression, and molecular diagnostic platforms, consumables, and services that run on SBS technology. In the past three years, Illumina has launched several products in the market, including the NovaSeqT 6000 v1.5 Reagent Kit, TruSight Software Suite, NextSeq 1000, and NextSeq 2000. To ensure continuous product development, the company invests a significant amount of its revenue on R&D. It also focuses on agreements with leading players to co-develop advanced technologies and strengthen its research & commercialization capabilities. In the past three years, Illumina has entered into agreements with Helix OpCo, LLC (US), Roche (Switzerland), and QIAGEN (Netherlands).

Thermo Fisher Scientific (US) held the second position in the metagenomic sequencing market in 2020. The company’s NGS sequencers run on Ion Semiconductor sequencing technology. Thermo Fisher will continue to have a strong market position owing to its robust platforms and consumables offerings. The company also has a significant geographic presence. It adopts organic and inorganic strategies such as collaborations, partnerships, and product launches to strengthen its market position. For instance, in September 2021, it codeveloped NGS-based companion diagnostics with AstraZeneca.

Related Reports:

Metagenomic Sequencing Market by Product & Services (Reagent, Consumables, Instrument), Workflow (Sample Preparation, Sequencing), Technology (16S rRNA, Shotgun, Whole-genome), Application (Drug Discovery, Diagnostic) - Global Forecast to 2027

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Report Code
BT 7350
RI Published ON
3/31/2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Metagenomic Sequencing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved